APA (7th ed.) Citation

Smolen, J. S., Genovese, M. C., Takeuchi, T., Hyslop, D. L., Macias, W. L., Rooney, T., . . . Winthrop, K. L. (2019). Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. Journal of rheumatology, 46(1), 7. https://doi.org/10.3899/jrheum.171361

Chicago Style (17th ed.) Citation

Smolen, Josef S., et al. "Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment." Journal of Rheumatology 46, no. 1 (2019): 7. https://doi.org/10.3899/jrheum.171361.

MLA (9th ed.) Citation

Smolen, Josef S., et al. "Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment." Journal of Rheumatology, vol. 46, no. 1, 2019, p. 7, https://doi.org/10.3899/jrheum.171361.